Ascendis Pharma (ASND) PT Lowered to $178 at Wedbush, After Pricing Public Offering At $142/ADS
Tweet Send to a Friend
Wedbush analyst Liana Moussatos lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $178.00 (from $188.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
